Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular diagnostics: an FDA perspective.

Ali M Ardekani1, Emanuel F Petricoin, Joseph L Hackett

  • 1Department of Therapeutic Proteins, CBER, FDA, Bethesda, MD 20892, USA. Ardekani@cber.fda.gov

Expert Review of Molecular Diagnostics
|March 22, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.

JCO precision oncology·2026
Same author

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling.

Cell death & disease·2026
Same author

Laser capture microdissection.

Nature reviews. Methods primers·2026
Same author

Immunoproteomic insights into inflammatory diseases of the critically endangered black rhinoceros (Diceros bicornis).

Scientific reports·2026
Same author

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

NPJ precision oncology·2026
Same author

Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomics.

NPJ precision oncology·2026
Same journal

Artificial intelligence in molecular diagnostics for pandemic preparedness.

Expert review of molecular diagnostics·2026
Same journal

Navigating PD-L1 testing in immuno-oncology: analytical robustness, clinical validation, and the role of the VENTANA SP263 assay.

Expert review of molecular diagnostics·2026
Same journal

Extracellular vesicles as diagnostic and prognostic biomarkers in non-small cell lung cancer.

Expert review of molecular diagnostics·2026
Same journal

Explainable epigenetic aging clocks: an overview of existing AI models and approaches.

Expert review of molecular diagnostics·2026
Same journal

Neuro-axonal injury biomarker serum neurofilament light chain is associated with osteoarthritis: a dual-cohort study from NHANES and UK Biobank.

Expert review of molecular diagnostics·2026
Same journal

Diagnostics and novel laboratory approaches to combat <i>Neisseria gonorrhoeae</i> antimicrobial resistance.

Expert review of molecular diagnostics·2026
See all related articles

Microarrays and in vitro diagnostics offer exciting potential for drug development and clinical monitoring. Realizing this potential requires collaboration between scientists, clinicians, and regulators to overcome implementation challenges.

Area of Science:

  • Biomedical science
  • Regulatory science
  • Medical technology

Background:

  • Microarrays and in vitro diagnostic devices enable global assessments of DNA, RNA, and proteins.
  • These technologies hold promise for pharmaceutical development, diagnostics, and therapeutic monitoring.

Purpose of the Study:

  • To explore the potential medical applications of microarrays and in vitro diagnostic devices.
  • To identify challenges and propose a framework for integrating these technologies into clinical practice.

Main Methods:

  • Review of current technological capabilities and potential applications.
  • Analysis of barriers to clinical and regulatory adoption.

Main Results:

  • Significant excitement exists regarding applications in drug selection, bedside diagnostics, and patient monitoring.

Related Experiment Videos

  • Transition from research to clinical practice faces hurdles related to clinician and regulatory scientist requirements.

    • Conclusions:

    • A collaborative framework involving regulators, product sponsors, and technology experts is crucial.
    • Successful integration can revolutionize drug development, regulatory science, medicine, and public health.